GlassScriptPhysician profile
Champa Chakraborti
NPI 1992927636
$856.18
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $357 · 2021: $206.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $233.77 | 2019-2021 | |
| Allergan, INC. | $102.50 | 2019-2020 | |
| Alkermes, INC. | $99.80 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94.83 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $75.24 | 2019-2021 | |
| Lundbeck LLC | $68.65 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $51.98 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $41.50 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $39.23 | 2020 | |
| Noven Therapeutics, LLC | $18.57 | 2021 | |
| Abbvie INC. | $15.52 | 2021 | |
| Eisai INC. | $14.59 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Champa Chakraborti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.